MESSAGE BY THE CHAIRMAN
OF THE BOARD OF DIRECTORS

Dear Stakeholders,

The year 2024 has been a period where different dynamics have come to the forefront in both global and local economies. Global uncertainties triggered by geopolitical tensions, inflationary pressures, and rising input costs have challenged economic balances. Despite these challenging conditions, DEVA Holding has successfully maintained its market position and demonstrated a sustainable performance. According to IQVIA data, in 2024, we ranked 3rd with a 5.3% market share in unit sales and 6th with a 2.9% market share in TL sales, reaffirming our strong presence in the industry.

For 66 years, DEVA has been committed to ensuring accessible healthcare for all. With our responsibility to build a sustainable future in mind, we continue to expand our portfolio and broaden our therapeutic areas. In 2024, we strengthened and diversified our portfolio with innovative products across 10 different therapeutic areas, particularly in cardiovascular system, dermatology, ophthalmology, hematology, systemic anti-infectives, and the nervous system. With our reliable, effective, and cost-efficient equivalent medicines, we remain dedicated to meeting the needs of patients in both Turkey and global markets.

Our three major production facilities in Çerkezköy and Kartepe, with an annual production capacity of 620 million units, successfully passed numerous inspections conducted by national and international health authorities in 2024. With EU GMP and US FDA approvals, we continue to manufacture at high global standards and make our products accessible to patients worldwide. In 2024, we further strengthened our presence in international markets, reaching a total of 1,404 product registrations across 82 countries. We expanded our portfolio in key regions such as Germany, New Zealand, Mexico, and the Middle East, reinforcing our competitive edge.

At the core of our sustainable success lies our unwavering commitment to R&D. Maintaining our leadership in this field, we were recognized as the pharmaceutical company with the highest R&D expenditure in Turkey in Turkishtime’s 2024 R&D 250 Report. With state-of-the-art laboratories and a team of 504 expert researchers, we continue to develop more effective and safer treatments for patients worldwide.

At DEVA, sustainability is not merely a goal but a fundamental principle embedded in our operations. We prioritize sustainability across every stage of our production, distribution, and supply chain. By utilizing our resources efficiently and fulfilling our environmental responsibilities, we aim to further expand access to medicine and contribute to global public health.

Dear Stakeholders,

With 66 years of experience, a strong leadership team, more than 3000 skilled employees, and an innovation-driven approach, we continue to make a difference in a rapidly evolving world. The successes we have achieved in the past fuel our determination for change, transformation, and innovation. Moving forward, we will remain committed to contributing to global healthcare and delivering value to all our stakeholders.

With my deepest regards,

Philipp Haas

Chairman of the Board of Directors & CEO